-
1 Comment
Aprea Therapeutics, Inc is currently in a long term downtrend where the price is trading 54.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Aprea Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 17.7% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 25.7% to $-13M since the same quarter in the previous year.
Based on the above factors, Aprea Therapeutics, Inc gets an overall score of 1/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US03836J1025 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 9M |
|---|---|
| PE Ratio | None |
| Target Price | 13.6667 |
| Beta | 1.64 |
| Dividend Yield | None |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for APRE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
